Edition:
United States

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

2.26USD
4:00pm EDT
Change (% chg)

$0.09 (+4.15%)
Prev Close
$2.17
Open
$2.16
Day's High
$2.27
Day's Low
$2.14
Volume
44,318
Avg. Vol
58,951
52-wk High
$6.27
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73
Thursday, 12 Oct 2017 07:00am EDT 

Oct 12 (Reuters) - Anavex Life Sciences Corp :Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients.Anavex Life Sciences Corp - ‍ANAVEX2-73 demonstrates desirable PK/PD properties.Anavex Life Sciences Corp - ‍clear concentration-effect relationship between ANAVEX2-73 and study measurements​.  Full Article

Anavex reports Q3 loss per share of $0.09
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Anavex Life Sciences Corp :Anavex reports fiscal third quarter 2017 financial results.Q3 loss per share $0.09.  Full Article

Anavex Life Sciences says selling security holder‍​ to issue 5 mln shares of common stock‍​
Friday, 26 May 2017 04:46pm EDT 

May 26 (Reuters) - Anavex Life Sciences Corp ::Anavex Life Sciences Corp says selling security holder‍​ to issue 5 million shares of common stock - sec filing ‍​.  Full Article

Anavex Q2 loss per share $0.04
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Anavex Life Sciences Corp :Anavex reports fiscal second quarter 2017 financial results.Q2 loss per share $0.04.Anavex life sciences corp - cash and equivalents of $23.4 million at march 31, 2017, compared to $9.2 million at september 30, 2016.  Full Article

Anavex Life Sciences provides update on lawsuit
Thursday, 30 Mar 2017 08:00am EDT 

Anavex Life Sciences Corp :Anavex life sciences corp reports dismissal of appeal in cortina lawsuit without payment of any fees or costs by company.  Full Article

Anavex reports Q1 loss per share $0.08
Tuesday, 7 Feb 2017 07:00am EST 

Anavex Life Sciences Corp - : Anavex reports fiscal first quarter 2017 financial results . Q1 loss per share $0.08 .Says it is now able to initiate subsequent placebo-controlled efficacy and safety trials for Anavex 2-73 in Alzheimer's and Parkinson's disease as well as rett syndrome.  Full Article

Anavex signs material transfer agreement with Biogen
Wednesday, 28 Sep 2016 07:00am EDT 

Anavex Life Sciences :Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73.  Full Article

Anavex Life Sciences says drug shows efficacy to support disease modification in Parkinson’s disease
Thursday, 22 Sep 2016 07:00am EDT 

Anavex Life Sciences Corp : Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints . Data indicates that ANAVEX 2-73 is well tolerated .Anavex life sciences’ drug shows efficacy to support potential disease modification in Parkinson’s disease.  Full Article

Anavex reports Q3 loss per share $0.06
Thursday, 11 Aug 2016 04:15pm EDT 

Anavex Life Sciences Corp : Anavex reports fiscal third quarter 2016 financial results . Q3 loss per share $0.06 . SEC staff recently advised company's legal counsel that staff did not intend to recommend enforcement action by commission .SEC staff advise relates to investigation previously described in company's 2015 report on form 10-K.  Full Article

Anavex confirms data from Phase 2a study of ANAVEX 2-73 in Alzheimer’s patients presented at AAIC 2016
Friday, 29 Jul 2016 09:20am EDT 

Anavex Life Sciences Corp : Anavex "remains dedicated" to advancing ANAVEX 2-73 and will be reporting new data to investors as it becomes available . Anavex confirms data from phase 2a study of ANAVEX 2-73 in alzheimer's patients presented at AAIC 2016 .Anavex confirms that there has been no change with regards to its science, data or fundamentals of company.  Full Article

BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia

* ANAVEX LIFE SCIENCES TO INITIATE PHASE 2 STUDY OF ANAVEX®2-73 IN PARKINSON’S DISEASE DEMENTIA AND PROVIDES CLINICAL STUDY UPDATE FOR ANAVEX®2-73 IN RETT SYNDROME